Articles On Botanix Pharmaceuticals (ASX:BOT)

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Botanix shares leap 17% on a solid start to the US rollout of the company’s anti-sweating treatment, Sofdra Radiopharm raises up to $40 million, while Orthocell banks $30 million Avita faces tough questions after surprise CEO departure B...

Botanix (ASX:BOT) was received warmly by some investors on Monday when its latest quarterly earnings report showed that revenues from anti-sweating drug Sofdra have increased to $7.1M, reflecting growth of around 65%, on top of the fact tha...

Highlights US CBD comments influence global cannabis sentiment ASX cannabis companies may benefit from regulatory shifts Australian medicinal cannabis landscape gains attention Explore how recent US CBD developments impact ASX-lis...

Highlights ASX 200 sees gains led by banks and telecoms Lithium stocks face sharp declines Defensive sectors provide market stability The ASX 200 continued to demonstrate market resilience, with major financial institutions like A...

Good Afternoon and welcome to HotCopper Highlights for Week 36, I’m Jon Davidson. In this segment the stocks you were watching and discussing the most this week on Australia’s number 1 finance website, let’s kick off with the most viewed....

4D Medical shares gain up to 40% on FDA lung imaging device approval Lumos wins US funding for kids’ flu-versus-virus trial ‘Spend money to make money’: the lesson from the last-minute reporters   In an “historic moment in respiratory dia...

 Plenty of biotechs are lodging late in the piece, but without too many ‘dog ate my homework’ excuses Telehealth group looks to post-pandemic recovery   Botanix, Amplia and Vitrafy pass muster with the brokers   Some students hand in thei...

Boss Energy (ASX:BOE) is the first top-trender on HotCopper forums in Week 31, with the uranium producer wowing holders and traders alike with its FY26 guidance for its Honeymoon Operation in South Australia. Listen to the HotCopper podc...

• Clarity Pharmaceuticals rocket up to 12% after its blitzkrieg placement • Artrya, Botanix and Imricor are among today’s quarterly updates • Lumos outlines US market potential   Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) h...

Highlights ASX 200 index trades close to record high Gains led by materials and coal stocks Peter Warren Automotive and Avita Medical see strong rallies The Australian share market advanced strongly on Wednesday, with...

Highlights Resources edge out banks in mixed ASX session Iron ore and gold miners post strong performances Iron ore prices rise as China boosts infrastructure The Australian share market ended the day on a...

Iron ore surges to four-month highs at US$104/tonne Gold lifts 1.4pc to five-week high Banks mostly lower as profit taking continues   Resource gains outweigh bank sell down It was a veritable tug of war on the ASX today as surging resour...

Welcome to this week’s HotCopper Wire, our market watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through the week’s biggest news headlines — and what they mean for Oz investors. In this Wee...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.4% to 8,557.4 points. Four ASX shares that are not letting that hold them back to...

POTUS threatens a foreign drug tariff, but gives Big Pharma more time to shift production onshore ASX drug makers say they won’t be overly affected by any Trump tariff whack Island Pharma acquires a secondary virus program   Donald Trump...

Orthocell is staging the US rollout of its Remplir device, including “pausing” enlisting too many distributors at once In Remplir’s first US commercial usage, an Ohioan surgeon has deployed the device successfully More than 300 investors t...

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are crashing down to Earth on Tuesday. In afternoon trade, the ASX 300 stock is down a whopping 55% to 14 cents. Why is this ASX 300 stock crashing? Investors have been selling the dermatology c...

While Tuesday has been a bit of a nothing trading day as Australian investors await the Reserve Bank’s July interest rate decision, there’ve still been some companies drawing buckets of attention on HotCopper forums. Listen to the HotCop...

The S&P/ASX 200 Index (ASX: XJO) has managed to get into positive territory on Tuesday. In afternoon trade, the benchmark index is up slightly to 8,595.5 points. Four ASX shares that have failed to follow the market higher today are lis...

Filling material supplier SDI pre-reports a flat result, partly because of declining amalgam sales Perspiring investors wipe more than 40% off Botanix share price after US market update   FDA approves Cochlear’s ‘smart’ implant system   V...

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind of government support, because a rare disease, by its very nature, implies a small addressable mar...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Highlights Clarity Pharmaceuticals tops ASX 300 with double-digit gains Bannerman Energy posts the steepest loss among major decliners Broad-based sector volatility reflects dynamic trading conditions Daily trading on...

ASX falls 8.4 points, which was about 0.1% Xero sheds 4.7% on $3.9b acquisition of Melio Payments Info tech sector slumps 2%   ASX edges lower on Xero acquisition The ASX 200 has fallen 8.4 points or 0.1% in trade today, after major infor...

Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon says investors shouldn’t rely just on management’s assertion that its anti-sweating drug Sofdra has – and we paraphrase – “the potential to be the world’s most successful dermatology d...

Little Green Pharma reports record revenue and a return to profits Botanix raises $48 million of debt for its anti-sweating drug, Sofdra The DNA of Genetic Technologies soon will be … financial advice   Little Green Pharma’s (ASX:LGP) Eur...

The ASX 200 has steadily climbed a fair bit higher from open, beating future predictions to add +0.7% through lunchtime trades today. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from...

Highlights Silver-focused companies on the ASX 200 and beyond lifted by multi-year highs in silver prices Small and mid-cap names such as Coronado Global and Antipa Minerals recorded strong movements Ora Banda Mining faced d...

Highlights Surge in prescriptions for medical cannabis is accelerating domestic production and diversification Regulatory advancements enabling broader patient access and product innovation Australia emerging as a regional h...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

Highlights ASX 200 moves near flatline after higher-than-expected CPI report weighs on early gains Webjet Travel Group (ASX:WEB) shares advance on FY25 update and strong FY26 outlook Goodman Group (ASX:GMG) and Fisher &...

Highlights Three ASX-listed penny stocks with market capitalisations above A$200 million Companies span sectors including lithium, technology, and biopharmaceuticals Share prices remain under one dollar despite large valuati...

 Investors with a short position in wound care house Polynovo face a nervous wait Oz drug stocks partly recover after swooning yesterday on Trump drug-pricing edict Wellnex Life rediscovers its sales mojo, while Elinixol Wellness goes to t...

Highlights Mineral Resources (MIN) observed increased market activity amid global trade updates. Elixir Energy (EXR) advanced following a new strategic direction led by recent leadership changes. Biotechnology stocks, includ...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is having a day to forget on Monday. In afternoon trade, the ASX 300 stock is down 18% to 38.2 cents. Why is this ASX 300 stock crashing? Investors have been selling Botanix and other h...

The S&P/ASX 200 Index (ASX: XJO) is starting the week on a positive note. At the time of writing, the benchmark index is up 0.35% to 8,260.2 points. Four ASX shares that have failed to follow the market higher today are listed below. H...

ASX edges up as Trump de-escalates China tariffs Copper jumps on Peru mine drama ResMed soars, GDG sinks, oil slips   The ASX had a bit of a spring in its step on the last trading day of the week, leaping higher by 0.6% as the mining big...

Highlights: Short interest remained elevated in uranium and lithium names, with some companies experiencing mild increases over the past week. Lifestyle Communities gained further short interest momentum following previous underp...

Global drug companies again are on the alert after Donald Trump reiterated his intention to impose a pharma tariff rumoured to be 25% No sweat! as Botanix raises $40 million in a placement Imricor’s ablation news lauded as a “truly groundb...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin ASX200 futures are pointing to a positive start, up 18 points, but US markets finish...

The All Ordinaries Index (ASX: XAO) is up 0.6% in morning trade, with this ASX All Ords healthcare share charging ahead of those gains. The outperforming stock in question is clinical dermatology company Botanix Pharmaceuticals Ltd (ASX: B...

Highlights: Several companies within the Australian market exhibit strong executive participation, reflecting confidence in their strategies. Businesses across various sectors, including resources, technology, and telecommunicati...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

ASX pharmaceutical companies are retaining their assets longer and advancing them to commercialisation LTR Pharma has established several commercialisation pathways for its novel nasal spray to treat erectile dysfunction  Botanix is indepe...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

ASX dips further amid tariff uncertainty Coal stocks fall after Macquarie downgrade Gold gains as ASX correction looms   The ASX saw fluctuations on Thursday, with early gains reversed in the afternoon as investor apprehension grew around...

Botanix elevated to S&P/ASX 300 index with share price more than doubling in past year Company’s Sofdra treatment for excessive underarm sweating approved by US FDA in June 2024 After a soft launch of Sofdra in the US, Botanix is rolli...